Stay updated on MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial
Sign up to get notified when there's something new on the MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial page.

Latest updates to the MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 has been added and Revision: v3.4.1 has been removed.SummaryDifference0.1%

- Check20 days agoChange DetectedThis is a minor metadata update: the revisions history shows Revision: v3.4.1, replacing v3.4.0, with no changes to study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page history shows Revision v3.3.4 added and Revision v3.3.3 removed.SummaryDifference0.1%

- Check64 days agoChange DetectedThe page history shows an added Revision: v3.3.3 and removal of the HHS Vulnerability Disclosure link, along with a prior Revision: v3.3.2; These are admin-level updates to the page metadata/footer and do not affect study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check93 days agoChange DetectedRevision: v3.3.2 added to the page history, replacing v3.2.0 and reflecting a platform/UI update rather than changes to study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check100 days agoChange DetectedThe page no longer displays a government funding and operating status notice that appeared at the top; this change does not affect the study record or its data.SummaryDifference0.5%

Stay in the know with updates to MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial page.